Jupiter Neurosciences, Inc. has a market cap of $131.5 million and recently conducted an IPO with Dominari Securities and Revere Securities as underwriters.
The company focuses on developing JOTROL, a resveratrol-based treatment for neuro-inflammation, created with Aquanova AG. JOTROL, a softgel capsule containing 100mg of resveratrol, uses a patented micellar technology to improve bioavailability.
Preclinical trials showed JOTROL has higher bioavailability than standard resveratrol. A Phase I trial in healthy volunteers was completed in 2021, and the results will guide further clinical studies. The company plans to launch Phase II trials for treating Parkinson’s Disease and rare diseases such as Mucopolysaccharidosis Type 1 (MPS-1) and MELAS.
Recent efforts include ongoing research partnerships in Southeast Asia, driven by rising interest in resveratrol due to its use in traditional herbal medicine. JOTROL has received patent approvals in Hong Kong and China and is viewed as a potential treatment for multiple conditions.
The chairman recently presented the company’s pipeline at the BIOHK 2023 conference, resulting in partnerships for regulatory and clinical trial management in Southeast Asia.
With aspirations for additional funding and a focus on enhancing treatment effectiveness while minimizing side effects, Jupiter Neurosciences is preparing for further clinical activities.
Founded in 2016, Jupiter Neurosciences has 4 employees and is located in Jupiter, Florida. For more information, visit their website.
Receive daily news & ratings for Jupiter Neurosciences Inc. – Enter your email address below for updates from MarketBeat.com.
`
